Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fulvestrant in recurrent or metastatic estrogen receptor-positive gynecologic malignancies
2017-005018-76Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in Endometrial Sarcoma (ESS), gynecological cancer, sponsored by UZ Leuven. Started Oct 2018; status: completed.
02
Drugs
fulvestrant
03
Conditions
Endometrial Sarcoma (ESS)gynecological cancer
Beyond the preview
Go deeper on 2017-005018-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005018-76.